EEG, ERPs, and EROs in patients with cognitive deficits due to progressive neurodegenerative diseases: The dark side of the precision medicine

Many millions of patients worldwide live with age-related progressive neurodegenerative diseases such as Alzheimer's, Parkinson's, Lewy body, and others belonging to severe cognitive deficits and disabilities in the activities of daily living (i.e., dementia) until death after a disease course of 10–15 years (Lemstra et al., 2017; Teipel et al., 2022). Indeed, no effective disease-blocking therapy is available to date. These diseases are caused by insufficient homeostasis of potentially neurotoxic proteins (e.g., amyloid, phospho tau, alpha-synuclein, TDP-43, light neurofibrillary chains) that progressively accumulate in the brain, affecting synaptic transmission and the generation and conduction of action potentials until neural loss (Lemstra et al., 2017; Jack Jr et al., 2018; Scott et al., 2022; Teipel et al., 2022).